Akari Therapeutics, Plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akari Therapeutics, Plc
The latest drug development news and highlights from our US FDA Performance Tracker.
The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he thinks Coversin, which inhibits leukotriene B4 as well as C5, may offer more benefits in certain orphan diseases.
Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.
Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft
David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board of directors, other execs join Merck, Apeiron Biologics, Vectura, Roivant, OncoSec, Breath Therapeutics, Immusoft and M3 Biotechnology.
- Other Names / Subsidiaries
- Celsus Therapeutics plc
- Morria Biopharmaceuticals, plc
- Volution Immuno Pharmaceuticals SA